ReviewCell proliferation2011
Cdc2: a monopotent or pluripotent CDK?
Review in Cell proliferation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 69 citations in OpenAlex.
- NFIX suppresses breast cancer cell proliferation by delaying mitosis through downregulation of CDK1 expression.Cell death discovery · 2025Article
- KIFC1 depends on TRIM37-mediated ubiquitination of PLK4 to promote centrosome amplification in endometrial cancer.Cell death discovery · 2024Article
- Article
- Macrophages maintain mammary stem cell activity and mammary homeostasis via TNF-α-PI3K-Cdk1/Cyclin B1 axis.NPJ Regenerative medicine · 2023Article
- Effect of Soybean Isoflavones on Proliferation and Related Gene Expression of Sow Mammary Gland Cells In Vitro.Animals : an open access journal from MDPI · 2022Article
- Application of Proteomics in the Discovery of Radiosensitive Cancer Biomarkers.Frontiers in oncology · 2022Review
- MTHFD2 promotes ovarian cancer growth and metastasis via activation of the STAT3 signaling pathway.FEBS open bio · 2021Article
- Carcinogenic effect of adenylosuccinate lyase (ADSL) in prostate cancer development and progression through the cell cycle pathway.Cancer cell international · 2021Article
- Article
- Mangiferin as New Potential Anti-Cancer Agent and Mangiferin-Integrated Polymer Systems-A Novel Research Direction.Biomolecules · 2021Review
- High Iodine Induces the Proliferation of Papillary and Anaplastic Thyroid Cancer CellsFrontiers in oncology · 2021Article
- Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest.Oncology reports · 2020Article
- miR-96-5p Suppresses the Progression of Nasopharyngeal Carcinoma by Targeting CDK1.OncoTargets and therapy · 2020Article
- Glycerin Monostearate Aggravates Male Reproductive Toxicity Caused by Di(2-ethylhexyl) Phthalate in Rats.Current medical science · 2019Article
- Triptolide Induces Glioma Cell Autophagy and Apoptosis via Upregulating the ROS/JNK and Downregulating the Akt/mTOR Signaling Pathways.Frontiers in oncology · 2019Article
- Inhibition of microRNA-19b promotes ovarian granulosa cell proliferation by targeting IGF-1 in polycystic ovary syndrome.Molecular medicine reports · 2018Article
- Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.Cellular and molecular life sciences : CMLS · 2018Article
- Genome-wide profiling of nardilysin target genes reveals its role in epigenetic regulation and cell cycle progression.Scientific reports · 2017Article
- SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.Oncotarget · 2017Article
- CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency.Cell death and differentiation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell cycle progression is controlled by both extracellular and intracellular signalling molecules. It has been generally believed that cdc2/CDK1 only control G(2)-M transition in mammalian and many other higher eukaryotic cells. Accumulating evidence shows that cdc2 not only promotes G(2)-M transition but is also capable of regulating G(1) progress and G(1)-S transition via association with multiple interphase cyclins; cdc2 activity can be inhibited by p21 and p27, two traditional G(1) CDK inhibitors. In addition, cdc2-cyclin B controls pronuclear union in interphase fertilized eggs. These data suggest that cdc2 may be a pluripotent CDK. Although mechanisms responsible for the multiple functions of cdc2 remain to be further investigated, interactions of cdc2 with pRb and with several important transcription factors may provide a clue to the pluripotent role of cdc2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.